ДИФФЕРЕНЦИАЛЬНО–ДИАГНОСТИЧЕСКИЕ КРИТЕРИИ НЕФРОПАТИЙ РАЗЛИЧНОЙ ЭТИОЛОГИИ (Обзор литературы)

doi: 10.25005/3078-5022-2024-1-3-316-335
Авторы:
О.З. Олимов
ГУ «Республиканский научно клинический центр урологии», Душанбе, Таджикистан

В данной обзорной статье представлены последние данные о дисметаболических, диабетических, туберкулезных, лекарственных и иммуноглобулин А нефропатиях. Отмечено, что несмотря на огромное многообразие этио–патогенетических механизмов развития нефропатий, при грамотно построенном диагностическом алгоритме и при учитывании всех доступных современных критериев диагностики, можно идентифицировать тот или иной вид нефропатии, что чрезвычайно важно для правильного выбора режима терапии больных с этими сложными заболеваниями.

Ключевые слова

Дисметаболические, диабетические, туберкулезные, лекарственные и иммуноглобулин А нефропатии.

Литература

  1. Yang Z, Feng L, Huang Y, Xia N. A differential diagnosis model for diabetic nephropathy and non–diabetic renal disease in patients with type 2 diabetes complicated with chronic kidney disease. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019;12:1963–1972.
  2. Cho N, Shaw J, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi:10.1016/j. diabres.2018.02.023.
  3. Walker J, Colhoun H, Livingstone S, et al. Type 2 diabetes, socio economic status and life expectancy in Scotland (2012–2014): a population–based observational study. Diabetologia. 2018;61 (1):108–116. doi:10.1007/s00125–017– 4478–x
  4. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316(6):602–610. doi:10.1001/jama.2016.10924.
  5. Lee YH, Kim K–P, Kim YG, et al. Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic–range proteinuria. Medicine. 2017;96(36):e8047. doi:10.1097/MD.0000000000008047.
  6. Li L, Zhang X, Li Z, et al. Renal pathological implications in type 2 diabetes mellitus patients with renal involvement. J Diabetes Complications. 2017;31(1):114–121. doi:10.1016/j.jdiacomp.2016. 10.024.
  7. Soleymanian T, Hamid G, Arefi M, et al. Non–diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome. Ren Fail. 2015;37(4):572–575. doi:10.3109/0886022X.2015.1007804.
  8. Liu S, Guo Q, Han H, et al. Clinicopathological characteristics of non diabetic renal disease in patients with type 2 diabetes mellitus in a north eastern Chinese medical center: a retrospective analysis of 273 cases. Int. Urol. Nephrol. 2016;48(10):1691–1698. doi:10.1007/s11255–016–1331–y.
  9. Wang1 Y, Tao Y. Tuberculosis–associated IgA nephropathy. Journal of International Medical Research. 2018; Vol. 46(7):2549–2557.
  10. Robert T, Berthelot L, Cambier A, et al. Molecular Insights into the Pathogenesis of IgA Nephropathy. Trends Mol Med 2015; 21: 762–775.
  11. Kendall EA, Azman AS, Cobelens FG, et al. MDR–TB treatment as prevention: The pro jected population–level impact of expanded treatment for multidrug–resistant tuberculo sis. PLoS One. 2017;12: e0172748.
  12. Gao YT, Sun L and Feng JM. Roles of mycobacterium tuberculosis ESAT–6 in the development of renal injury. Int J Clin Exp Med 2015; 8: 21964–21974.
  13. Li S, Siyuan T, Jiangmin F, et al. Analysis of the association between Mycobacterium tuberculosis infection and Immunoglobulin A nephropathy by early secreted antigenic target 6 detection in renal biopsies: a pro spective study. Postgrad Med 2017; 129: 307–311.
  14. Shinke H, Masuda S, Togashi Y, et al. Urinary kidney injury molecule–1 and monocyte chemotactic protein–1 are noninvasive biomarkers of cisplatin–induced nephrotoxicity in lung cancer patients. Cancer Chemother. Pharmacol. 2015;76(5):989–996.
  15. Pavkovic M, Robinson–Cohen C, Chua AS, et al. Detection of drug– induced acute kidney injury in humans using urinary KIM–1, miR–21, −200c, and −423. Toxicol. Sci. 2016;152(1):205–513.
  16. George B, Wen X, Mercke N, et al. Profiling of kidney injury biomarkers in patients receiving cisplatin: time–dependent changes in the absence of clinical nephrotoxicity. Clin. Pharmacol. Ther. 2017;101(4):510–518.
  17. Tekce BK, Uyeturk U, Tekce H, et al. Does the kidney injury molecule–1 predict cisplatin–induced kidney injury in early stage? Ann. Clin. Biochem. 2015;52(Pt 1):88–94.
  18. Hosohata K, Washino S, Kubo T, et al. Early prediction of cisplatin– induced nephrotoxicity by urinary vanin–1 in patients with urothelial carcinoma. Toxicology. 2016;359–360:71–75.
  19. Slabiak–Blaz N, Adamczak M, Gut N, et al. Administration of cyclosporine A in pregnant rats–the effect on blood pressure and on the glomerular number in their offspring. Kidney Blood Press Res. 2015;40(4):413–423.
  20. Park HS, Kim EN, Kim MY, et al. The protective effect of neutralizing high–mobility group box1 against chronic cyclosporine nephrotoxicity in mice. Transpl. Immunol. 2016;34:42–49.
  21. George B, Joy MS, Aleksunes LM. Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp. Biol. Med. (Maywood) 2018;243(3):272–282.
  22. Argyropoulos CP, Chen SS, Ng YH, et al. Rediscovering beta–2 microglobulin as a biomarker across the spectrum of kidney diseases. Front. Med. (Lausanne). 2017;4:73.
  23. Gautier JC, Gury T, Guffroy M, et al. Comparison between male and female Sprague–Dawley rats in the response of urinary biomarkers to injury induced by gentamicin. Toxicol. Pathol. 2014;42(7): 1105–1116.
  24. Nishijima T, Kurosawa T, Tanaka N, et al. Urinary beta2 microglobulin can predict tenofovir disoproxil fumarate–related renal dysfunction in HIV–1–infected patients who initiate tenofovir disoproxil fumarate–containing antiretroviral therapy. AIDS. 2016;30(10):1563–1571.
  25. Lebherz–Eichinger D, Tudor B, Ankersmit HJ, et al. Trefoil factor 1 excretion is increased in early stages of chronic kidney disease. PLoS One. 2015;10(9):e0138312.
  26. Edelstein CL. Biomarkers in acute kidney injury. In: Edelstein CL, editor. Biomarkers of kidney disease 2nd ed. London: Elsevier; 2017: 241–303.
  27. Pianta TJ, Pickering JW, Succar L, et al. Dexamethasone modifies cystatin c–based diagnosis of acute kidney injury during cisplatin–based chemotherapy. Kidney Blood Press Res. 2017;42(1):62–75.
  28. Dodgshun AJ, Quinlan C, Sullivan MJ. Cystatin C based equation accurately estimates glomerular filtration rate in children with solid and central nervous system tumours: enough evidence to change practice? Pediatr. Blood Cancer. 2016;63(9):1535–1538.
  29. Whiting P, Birnie K, Sterne JAC, et al. Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data. Support Care Cancer. 2018;26(5):1635–1644.
  30. Karimzadeh I, Khalili H. Comparison between a serum creatinine–and a cystatin C–based glomerular filtration rate equation in patients receiving amphotericin B. Daru. 2016;24(1):16.
  31. Lau L, Al–Ismaili Z, Harel–Sterling M, et al. Serum cystatin C for acute kidney injury evaluation in children treated with aminoglycosides. Pediatr. Nephrol. 2017;32(1):163–171.
  32. Barreto EF, Rule AD, Voils SA, et al. Innovative use of novel biomarkers to improve the safety of renally–eliminated and nephrotoxic medications. Pharmacotherapy. 2018;38(8):794–803.
  33. Bunel V, Tournay Y, Baudoux T, et al. Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers. Clin Kidney J. 2017;10(5):639–647.
  34. Sterling M, Al–Ismaili Z, McMahon KR, et al. Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy. Pediatr. Blood Cancer. 2017;64(10).
  35. Feinstein J, Ramkhelawon B. Netrins & Semaphorins: Novel regulators of the immune response. Biochim Biophys Acta. 2017;1863(12):3183–3189.
  36. De Palma G, Sallustio F, Schena FP. Clinical application of human urinary extracellular vesicles in kidney and urologic diseases. Int J Mol Sci 2016;17(7).
  37. Dusse F, Edayadiyil–Dudasova M, Thielmann M, et al. Early prediction of acute kidney injury after transapical and transaortic aortic valve implantation with urinary G1 cell cycle arrest biomarkers. BMC Anesthesiol. 2016;16(1):76–88.
  38. Gist KM, Goldstein SL, Wrona J, et al. Kinetics of the cell cycle arrest biomarkers (TIMP2*IGFBP–7) for prediction of acute kidney injury in infants after cardiac surgery. Pediatr Nephrol. 2017;32(9):1611–1619.
  39. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery– associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43(11):1551–1561.
  40. Vijayan A, Faubel S, Askenazi DJ, et al. Clinical Use of the Urine Biomarker [TIMP–2] x [IGFBP7] for Acute Kidney Injury Risk Assessment. Am. J. Kidney Dis. 2016;68(1):19–28.
  41. Toprak Z, Cebeci E, Helvaci SA, et al. Cisplatin nephrotoxicity is not detected by urinary cell cycle arrest biomarkers in lung cancer patients. Int. Urol. Nephrol. 2017;49(6):1041–1047.
  42. Schanz M, Hoferer A, Shi J, et al. Urinary TIMP2IGFBP7 for the prediction of platinum–induced acute renal injury. Int. J. Nephrol. Renovasc. Dis. 2017;10:175–181.
  43. Brunet M, Shipkova M, van Gelder T, et al. Barcelona Consensus on biomarker–based immunosuppressive drugs management in solid organ transplantation. Ther. Drug Monit. 2016;38:S1–20.

Сведения об авторах

Олимов Олим Зафархонович,
врач-уролог ГУ «Республиканский научно клинический центр урологии»

Информация об источнике поддержки в виде грантов, оборудования, лекарственных препаратов
Финансовой поддержки со стороны компаний–производителей лекарственных препаратов и медицинского оборудования авторы не получали.

Конфликт интересов: отсутствует

Адрес для корреспонденции

Олимов Олим Зафархонович,
врач-уролог ГУ «Республиканский научно клинический центр урологии»,

E-mail: olimkhon.alimov@gmail.com

Тел.: +992-557007097.

◄ Возврат к списку